NHEJ1: A Potential Drug Target and Biomarker (G79840)

Target Name: NHEJ1

NCBI ID: G79840

NHEJ1

NHEJ1: A Potential Drug Target and Biomarker

Non-homologous end joining factor 1 (NHEJ1) is a protein that plays a critical role in DNA repair and may also be a drug target and biomarker. NHEJ1 is a transmembrane protein that is expressed in various tissues and cells, including blood cells, epithelial cells, and cancer cells. NHEJ1 has four known splice variants, which may result in different levels of expression and function.

The function of NHEJ1 is to repair DNA damage in the cell. DNA damage can occur due to various factors, such as ionizing radiation, mutations, or in some diseases, such as cancer. NHEJ1 helps in the repair of DNA damage by ensuring that the broken ends of the double helix are joined back together correctly. This process is crucial for maintaining the genetic integrity of the cell and is a critical step in the DNA repair pathway.

NHEJ1 is also involved in apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body. During apoptosis, NHEJ1 helps in the formation of a protein complex that targets and destroys damaged DNA. This process is essential for maintaining tissue homeostasis and may be a potential drug target for cancer therapies.

In addition to its role in DNA repair and apoptosis, NHEJ1 may also be a biomarker for some diseases. For instance, NHEJ1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that targeting NHEJ1 may be an effective way to enhance cancer treatments.

NHEJ1 has also been shown to be involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. NHEJ1 plays a role in ensuring that cells stick together and maintain their proper position, which is essential for tissue development and repair.

In conclusion, NHEJ1 is a protein that is involved in various cellular processes that are critical for maintaining tissue homeostasis. The role of NHEJ1 in DNA repair, apoptosis, and cell adhesion makes it an attractive drug target and a potential biomarker for some diseases. Further research is needed to fully understand the functions of NHEJ1 and its potential as a drug target and biomarker.

Protein Name: Non-homologous End Joining Factor 1

Functions: DNA repair protein involved in DNA non-homologous end joining (NHEJ); required for double-strand break (DSB) repair and V(D)J recombination (PubMed:16439204, PubMed:16439205, PubMed:17717001, PubMed:17317666, PubMed:17470781, PubMed:18644470, PubMed:20558749, PubMed:26100018, PubMed:18158905). Plays a key role in NHEJ by promoting the ligation of various mismatched and non-cohesive ends (PubMed:17717001, PubMed:17470781, PubMed:19056826). Together with PAXX, collaborates with DNA polymerase lambda (POLL) to promote joining of non-cohesive DNA ends (PubMed:30250067, PubMed:25670504). May act in concert with XRCC5-XRCC6 (Ku) to stimulate XRCC4-mediated joining of blunt ends and several types of mismatched ends that are non-complementary or partially complementary (PubMed:16439204, PubMed:16439205, PubMed:17317666, PubMed:17470781). Associates with XRCC4 to form alternating helical filaments that bridge DNA and act like a bandage, holding together the broken DNA until it is repaired (PubMed:22228831, PubMed:26100018, PubMed:28500754, PubMed:27437582, PubMed:21775435, PubMed:22287571, PubMed:21768349). The XRCC4-NHEJ1/XLF subcomplex binds to the DNA fragments of a DSB in a highly diffusive manner and robustly bridges two independent DNA molecules, holding the broken DNA fragments in close proximity to one other (PubMed:28500754, PubMed:27437582). The mobility of the bridges ensures that the ends remain accessible for further processing by other repair factors (PubMed:27437582). Binds DNA in a length-dependent manner (PubMed:17317666, PubMed:18158905)

The "NHEJ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NHEJ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets